Taysha Gene Therapies — Third Quarter 2026 Earnings Summary

Taysha Gene Therapies reported a net loss of $39.1 million for the third quarter of 2026, driven by increased research and development expenses related to its TSHA-102 clinical trials. The company successfully completed a BLA-enabling Process Performance Qualification manufacturing campaign for TSHA-102, which met all predefined product specifications and comparability criteria. As of November 2026, TSHA-102 has been generally well tolerated across 33 patients in the REVEAL and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed. Taysha expects to report topline data from the six-month interim analysis of the REVEAL pivotal trial and receive FDA feedback on its BLA submission pathway in the first half of 2027.